Compare Invesco Preferred ETF (PGX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco Preferred ETF trades at $10.46, while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| PGX | XBI | |
|---|---|---|
52-Week High | $11.87 | $169.55 |
52-Week Low | $10.46 | $93.43 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.49 with no change in the last 24 hours. Technical indicators show a bearish trend from moving averages but bullish signals from oscillators, with support at $10 and resistance at $11. Recent corporate actions include dividends declared for H1-26 and H2-26, though key financial ratios are unavailable for fundamental assessment.
The outlook remains uncertain due to limited financial data. Opportunities include dividend income, but risks stem from the lack of transparency in earnings and valuation metrics. Investors should seek updated SEC filings for a clearer picture of the company's health and growth prospects.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
